Third Time Lucky As Japan Finally Approves Shionogi’s Oral COVID Antiviral
Simpler Dosing To Help Xocova?
Shionogi’s once-daily oral COVID-19 antiviral finally gets Japan approval after being considered for the third time by an expert panel, paving the way for public availability of the country’s first such home-grown option in early December.
You may also be interested in...
Xocova’s emergency approval stymied by uncertainties over efficacy and other characteristics that could effectively limit its use, prompting decision to await Phase III data later this year.
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
With Qdenga’s US approval process moving ahead with the granting of a Priority Review and the dengue vaccine's first market launch, in Indonesia, expected early next year, Takeda has recently referred to plans to expand the product into other countries as well. But precise timings as yet remain unclear.